Ceapro Inc.
Other OTC•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Company Description
- CEO
- Mr. Gilles R. Gagnon ICD.D, M.B.A., M.Sc.
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 7824 – 51 Avenue NW Edmonton AB Canada T6E 6W2
- IPO Date
- Jan 8, 2021
- Website
- ceapro.com
- Similar Companies
- Business
- Ceapro Inc., a biotechnology company, engages in the development and marketing of health and wellness products and technology relating to plant extracts in the United States, Germany, China, Canada, and internationally. It operates in two segments, Active Ingredient Product Technology Industry and Cosmeceutical Industry. The Active Ingredient Product Technology Industry segment develops proprietary extraction technologies and the application of these technologies to the production, development, and commercialization of active ingredients, such as oat beta glucan and avenanthramides, which are derived from oats and other renewable plant resources for healthcare and cosmetic industries. The Cosmeceutical Industry segment is involved in the development and commercialization of anti-aging products derived from natural active ingredients sold directly to the end-user primarily through online website sales and through select natural products stores. The company was incorporated in 1997 and is headquartered in Edmonton, Canada.
Company News
Shareholder Alert: Ademi LLP investigates whether Aeterna Zentaris Inc.'s transaction with Ceapro was Fair to Shareholders
Aeterna Zentaris and Ceapro Complete Merger Transaction
Aeterna Zentaris and Ceapro Complete Merger Transaction
Ceapro Inc. Reports Financial Results for First Quarter 2024 and Provides Corporate Update
Aeterna Zentaris Announces Details Regarding Transaction with Ceapro
Ceapro Inc. Reports 2023 Financial Results and Operational Highlights
Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris
Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings
Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company
Ceapro Provides Business Update on Progress of Ongoing Development Programs, Technology and Cosmeceutical Base Business
Ceapro Inc. Announces the Mailing of Meeting Materials in Connection With the Special Meeting of Securityholders to Approve Merger With Aeterna Zentaris
Ceapro Inc. Announces Dosing of First Patients in Phase 1-2a Study Assessing Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases
Ceapro Inc. Reports 2023 Third Quarter and Nine-Month Financial Results and Operational Highlights
Ceapro Inc. Initiates Phase 1-2a Study Assessing Its Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases
Ceapro Inc. Enters into Technical Collaboration with NATEX Prozesstechnologie GmbH and Provides Update on the Scale-Up Project for its Patented Pressurized Gas eXpanded (PGX) Technology
Ceapro Inc. Reports 2023 Second Quarter and Six-Month Financial Results and Provides Corporate Update
Ceapro Extends Exclusive International Supply and Distribution Agreement with Leading Global Provider of Active Ingredients, Symrise
Ceapro Announces Next Phase of Research Collaboration with the Angiogenesis Foundation
Ceapro to Present at the Virtual Investor 2023 Companies to Watch Event
Ceapro: A Moat In Oat